News

Roche announced that it has entered into a collaboration with Eli Lilly and Company to support the development of Roche’s Elecsys Amyloid Plasma Panel (EAPP). The EAPP is an innovative…
Read More...

Regeneron Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) has extended the approval of Evkeeza (evinacumab-dgnb) as an adjunct to other lipid-lowering…
Read More...

Biohaven Ltd. announced that it acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus…
Read More...

Jacobio Pharma announced it has entered into a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA to evaluate the combination of Jacobio's CD73 monoclonal antibody…
Read More...

Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1),…
Read More...

Hovione and Laxxon Medical announced a strategic collaboration to advance the use of 3D screen printing technologies for the pharmaceutical industry. This partnership combines Laxxon´s…
Read More...

Marinus Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to ganaxolone for the treatment of Lennox-Gastaut…
Read More...

Dewpoint Therapeutics announced a research and development partnership with Novo Nordisk to identify drug candidates using Dewpoint's discovery platform related to biomolecular…
Read More...

Invitae and Deerfield Management Company announced a partnership to advance genetics-based drug discovery and development in rare disease. The partnership will leverage genetics and…
Read More...

The European Commission (EC) has approved Dupixent (dupilumab) in the European Union (EU) to treat severe atopic dermatitis in children aged 6 months to 5 years old who are candidates…
Read More...

Gilead Sciences, Inc. and Nurix Therapeutics, Inc. announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule…
Read More...

Coya Therapeutics, Inc. a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today…
Read More...

Predictive Oncology Inc. together with Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder of cancer research, Cancer Research UK (CRUK),…
Read More...

Arrowhead Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with…
Read More...

Syneos Health announced a strategic multi-year agreement with Microsoft. Utilizing Microsoft Azure services, Syneos Health has developed an advanced analytics platform that enables…
Read More...

BioNTech SE and OncoC4, Inc. announced that they have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize OncoC4’s next-generation…
Read More...

Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug delivery company, have entered a…
Read More...

Ipsen announced that the U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) goal date, for the resubmitted New Drug Application (NDA) for investigational…
Read More...

InvisiShield Technologies Ltd., a pre-clinical-stage biotechnology company focused on developing intranasal preventives for major disease-causing respiratory viruses, announced a…
Read More...

Processa Pharmaceuticals, Inc. announced that the Company has dosed the first patient in its NGC-Capecitabine (combination of PCS6422 and capecitabine) 300 mg dose group. The Processa…
Read More...